We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Myconostica Announces CE Marking of MycAssay™ Aspergillus for Serum


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Myconostica Announces CE Marking of MycAssay™ Aspergillus for Serum"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Myconostica Ltd announces the CE marking of its product MycAssay™ Aspergillus for detection of Aspergillus DNA in serum.

The CE marking is in addition to the existing CE marking for respiratory samples means, that MycAssay™Aspergillus is now CE marked for all major sample types.

MycAssay™ Aspergillus is a molecular diagnostic test for the detection of Aspergillus spp DNA. The kit is designed to be used by qualified laboratory professionals; the results provided by MycAssay™ Aspergillus aid physicians to make a diagnosis in patients suspected of having an infection caused by Aspergillus. It provides rapid and accurate results to physicians, enabling appropriate drug treatments to be administered thereby improving patient outcomes.

Dr. John Thornback, Myconostica’s Chief Business Officer, said: “It is becoming increasingly recognized that Aspergillus DNA is present in serum and its measurement can be important in aiding the diagnosis of Aspergillus infections. There are a number of different high risk patient groups for whom it is difficult to obtain respiratory samples. The CE marking of MycAssay™ Aspergillus for serum now enables serum samples from these at risk patients to be tested using a fully validated assay.
Advertisement